Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

LKB1 and SAD kinases define a pathway required for the polarization of cortical neurons.
A study to evaluate the effect of ultrasound treatment on nodules in multiple sclerosis patients.
Disease-modifying drugs for multiple sclerosis in pregnancy: A systematic review.
Zebrafish as a model to investigate CNS myelination.
Classification of individuals based on ex-vivo glatiramer acetate-induced interferon-γ and interleukin-4 response.
Accumulation and therapeutic modulation of 6-sulfo LacNAc(+) dendritic cells in multiple sclerosis.
The effects of diet on the severity of central nervous system disease: One part of lab-to-lab variability.
Susceptibility tensor imaging (STI) of the brain.
Quantification of normal-appearing white matter tract integrity in multiple sclerosis: a diffusion kurtosis imaging study.
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes.
Laquinimod in Relapsing-Remitting Multiple Sclerosis
Predictors of long-term disability accrual in relapse-onset multiple sclerosis.
Preclinical studies of sex differences: a clinical perspective.
Genetic variation in the IL7RA/IL7 pathway increases multiple sclerosis susceptibility.
Developmental Origin of Oligodendrocyte Lineage Cells Determines Response to Demyelination and Susceptibility to Age-Associated Functional Decline.
CHMP issues positive opinion for TECFIDERA™ (dimethyl fumarate) as a first-line treatment for multiple sclerosis in the European Union
Specific inhibition of secreted NRG1 types I-II by heparin enhances Schwann Cell myelination.
Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.
Time course of clinical and neuroradiological effects of delayed-release dimethyl fumarate in multiple sclerosis.
Subclinical primary retinal pathology in neuromyelitis optica spectrum disorder.
Genzyme Announces Successful Phase III Results for Alemtuzumab (LEMTRADA TM*) in Multiple Sclerosis
Rapid exacerbation of multiple sclerosis following the initiation of interferon-β: report of nine cases.
European Medicines Agency accepts Marketing Authorization Application for conditional approval of masitinib in the treatment of pancreatic cancer
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis ((DECIDE))
Dimethyl Fumarate and Monoethyl Fumarate Exhibit Differential Effects on KEAP1, NRF2 Activation, and Glutathione Depletion In Vitro.

Pages